16893-05-3

Basic information

• Product Name: CIS-TETRACHLORODIAMMINE PLATINUM (IV)
• Synonyms: TRANS-DIAMMINETETRACHLOROPLATINUM(IV);TRANS-TETRACHLORODIAMMINE PLATINUM (IV);(oc-6-22)-platinu;(z)-platinum(iv;cis-diamminotetrachloroplatinum;cis-platinum(iv)diamminotetrachloride;cis-platinumdiamminetetrachloride;nsc119876
• CAS NO: 16893-05-3
• Molecular Formula: Cl₄H₆N₂Pt
• Molecular Weight: 370.95
• EINECS: 240-930-6
• Product Categories: Metal and Ceramic Science;Platinum Salts;Salts;metal-ammine complexes
• Mol File: 16893-05-3.mol
• Article Data: 8

Chemical Properties

• Melting Point: >300 °C(lit.)
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: yellow/Powder
• Density: g/cm³
• CAS DataBase Reference: CIS-TETRACHLORODIAMMINE PLATINUM (IV)(CAS DataBase Reference)
• NIST Chemistry Reference: CIS-TETRACHLORODIAMMINE PLATINUM (IV)(16893-05-3)
• EPA Substance Registry System: CIS-TETRACHLORODIAMMINE PLATINUM (IV)(16893-05-3)

Safety Data

• Hazard Codes: Xi,T
• Statements: 36/37/38-42/43-41-25
• Safety Statements: 26-36-45-36/37/39-22
• RIDADR: 2811
• WGK Germany: 3
• RTECS: TP2485803
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 16893-05-3(Hazardous Substances Data)

Usage

General Description

CIS-TETRACHLORODIAMMINE PLATINUM (IV) is a chemotherapy drug used to treat various types of cancer, including ovarian, testicular, and lung cancer. It works by targeting and stopping the growth of cancer cells. This medication is administered through intravenous infusion, and the dosage depends on the type and stage of cancer being treated. Common side effects of CIS-TETRACHLORODIAMMINE PLATINUM (IV) include nausea, vomiting, and decreased blood cell counts, which can increase the risk of infection and bleeding. Patients taking this medication may also experience hair loss, loss of appetite, and fatigue. It is important to follow the prescribed treatment schedule and closely monitor for any adverse reactions while taking CIS-TETRACHLORODIAMMINE PLATINUM (IV).

InChI:InChI=1/4ClH.2H2N.Pt/h4*1H;2*1H2;/q;;;;2*-1;+6/p-4/rCl4Pt.2H2N/c1-5(2,3)4;;/h;2*1H2/q+2;2*-1

Upstream product

• 10026-13-8 phosphorus pentachloride 
• 26035-31-4 transplatin 
• 104853-65-8 diamminedichloro(dichloramido)hydroxoplatinum(IV) 
• 15663-27-1 cisplatin 
• 7647-14-5 sodium chloride 
• 7782-50-5 chlorine 
• 7647-01-0 hydrogenchloride 
• 10025-99-7 potassium tetrachloroplatinate(II) 
• 41575-87-5 cis-diaminedinitroplatinum(II) 
• 25478-67-5 tetraethylammonium tetrachloroaurate(III) 

Downstream Products

• 15663-27-1 cisplatin 
• 16893-05-3 cis-diaammineplatinum(IV) tetrachloride 
• 26035-31-4 transplatin 
• 26035-31-4 cisplatine 

Relevant articles and documents

Halogenated PtIV Complexes from N-Halosuccinimide Oxidation of PtII Antitumor Drugs: Synthesis, Mechanistic Investigation, and Cytotoxicity

Compared with square-planar PtII drugs, PtIV-based anticancer prodrugs are relatively inert under physiological conditions and can be activated after entering cells. The two axial ligands in PtIV complexes provide an opportunity to further functionalize these prodrugs. In recent years, much effort has been devoted to developing new PtIV-based anticancer prodrugs with higher cytotoxicity but fewer side effects. New synthetic methods, however, are intensely desired for structurally diversified and biologically distinct PtIV complexes. Herein, we utilize N-halosuccinimides as oxidants and carry out the oxidation reaction on PtII drugs including cisplatin, carboplatin, and oxaliplatin to obtain halogenated PtIV complexes. The related mechanism of the reaction of N-bromosuccinimide (NBS) with cisplatin in ethanol is thoroughly investigated. N-chlorosuccinimide is also utilized to obtain the respective dichlorinated PtIV complexes. When N-iodosuccinimide reacts with PtII drugs, new PtIV compounds containing iodide and succinimide ligands in the axial position are formed. Cytotoxicity test shows that some of the complexes are active against cisplatin-resistant human ovarian cancer cells. Our study provides a detailed understanding of the reaction mechanism between NBS and cisplatin and offers a more convenient strategy to obtain dichlorinated and new iodinated PtIV anticancer prodrugs.

CIS-OXOPLATIN FOR TREATING STOMACH CANCER

The invention relates to a pharmaceutical composition comprising cis-oxoplatin, or a salt and/or derivative thereof, for use as a medicament in the treatment and/or preventation of stomach cancer. The invention further relates to the pharmaceutical composition as described for use in the treatment of stomach cancer, wherein the cis-oxoplatin or derivative thereof is administered in a form that is transformed under acidic pH to a tetrachloro-oxoplatin (IV).